Amycretin, targeting both GLP-1 and amylin receptors simultaneously, produced remarkable weight reductions of up to 24.3% over 36 weeks with subcutaneous administration in recent trials. The dual mechanism engages hindbrain satiety pathways while delaying gastric emptying, creating synergistic effects that surpass single-target approaches. These results represent a significant advancement in obesity pharmacotherapy, potentially addressing the efficacy plateau that has limited current GLP-1 receptor agonists like semaglutide, which typically achieve 15-17% weight loss. The magnitude of weight reduction approaches what's seen with bariatric surgery, marking a potential paradigm shift in non-surgical obesity treatment. However, this appears to be a review paper synthesizing existing trial data rather than presenting new clinical findings. The safety profile aligns with existing incretin-based therapies, though long-term cardiovascular and renal outcomes remain to be established. If these efficacy rates hold up in larger, longer-term studies, amycretin could become the new gold standard for obesity pharmacotherapy, particularly when combined with complementary agents like SGLT2 inhibitors for comprehensive metabolic management.